Discovery Programs

Drug Discovery

Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit to a clinically ready candidate with balanced properties and strong IP protection. We handle any type of peptide, and all our work is done in-house to ensure quality and speed.

Why Gubra?

Expertise in peptide drugs
One-stop shop for peptide drug discovery
AI/ML-driven drug discovery platform
Fast delivery of clinical candidates
Proven track record of successful programs

Consult with Lise Biehl Rudkjær

Director, Business Development

Choose the right, trustworthy discovery partner.

ML/AI-driven Peptide Drug Discovery

The streaMLine platform

The streaMLine platform is our ML/AI-driven platform for peptide drug discovery. We use high-throughput AI-driven data analysis and peptide library designs. We optimize several parameters in parallel to quickly obtain the best clinical candidate. All our work is done in-house to ensure its quality.

“

The streaMLine platform enables smarter and faster peptide drug discovery.

Discover our unique ML/AI-driven platform developed by in-house experts.

In-house data generation – high quality & speed

One-stop shop for peptide drug discovery

Peptide synthesis

Customized peptide libraries
4000+ peptides per month
Linear peptides, cyclic peptides
Natural & unnatural amino acids
Half-life extenders, linkers, and fluorophore labeling

In vitro pharmacology

Agonist & antagonist
Internalization
Protein-protein interactions

CMC

Solubility
Physical stability
Chemical stability

Bioanalysis

PK
Metabolite identification
Exposure analysis

In vivo pharmacology

Expert CRO in rodent in vivo pharmacology
Golden-standard models in all indications related to metabolic and fibrotic diseases
Sophisticated in-vivo endpoints
Supported by assay, histology, imaging and NGS facilities